TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed unresectable local advanced/recurrent or metastasis esophageal squamous cell carcinoma;~2. No previous systemic anti-tumor treatment;~3. Subjects must have at least one measurable tumor lesion per RECIST 1.1;~4. Tissue samples should be provided for biomarkers (such as PD-L1) analysis;~5. ECOG: 0-1;~6. Adequate organ and bone marrow function;~Exclusion Criteria:~1. Allergic to monoclonal antibodies, any SHR-1210 components, paclitaxel, cisplatin and other platinum drugs;~2. Prior therapy as follow:~   1. Anti-PD-1 or anti-PD-L1;~  2. Any experimental drugs within 4 weeks of the first dose of study medication;~  3. Received major operations or serious injuries within 4 weeks of the first dose of study medication;~  4. Received last dose of anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within 4 weeks of the first dose of study medication;~3. Not recovered to ≤CTCAE 1 from adverse events (except for hair loss) due to a previously anti-tumor treatment;~4. Subjects with any active autoimmune disease or history of autoimmune disease;~5. Pregnancy or breast feeding;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SHR-1210 + paclitaxel + cisplatin (Type: EXPERIMENTAL): Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，SHR-1210 200mg，Day 2，every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance
- placebo+paclitaxel + cisplatin (Type: ACTIVE_COMPARATOR): Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，placebo，Day 2，every 3 weeks, maximum 6 cycles, then placebo maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia~* Measurable disease~* Have received at least one prior therapy for WM therapies~* Disease free of prior malignancies~* Able to adhere to study visit schedule and other protocol requirement~Exclusion Criteria:~* Pregnant or breastfeeding~* Any other serious medical condition~* Concurrent use of other anti-cancer agents or treatments~* Prior exposure to PCI-32765~* Known CNS lymphoma~* Significant cardiovascular disease~* Any disease affecting gastrointestinal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): PCI-32765; ibrutinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Effects of Compression in POTS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosis of Postural Tachycardia Syndrome (POTS)~* Age 18-60 years (we are an adult group and we do not see pediatric patients clinically and do not have appropriate pediatric expertise)~* Male and Female~* Able and willing to provide informed consent~* Ability to travel to Libin Cardiovascular Institute of Alberta Autonomic Testing Lab at the University of Calgary, Calgary, AB.~Exclusion Criteria:~* Overt cause for postural tachycardia, i.e., acute dehydration~* Participants with somatization or severe anxiety symptoms will be excluded (as they may not tolerated study procedures)~* Pregnant women~* Inability to tolerate compression garment for the duration of the study~* Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Full Compression (Type: EXPERIMENTAL): The LifeWrap compression garment will be fully secured with all straps.
- Abdominal and Pelvic Compression (Type: EXPERIMENTAL): The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.
- Lower Limb Compression (Type: EXPERIMENTAL): The Lifewrap compression garment calf and ankle straps only will be secured.
- No Compression (Type: NO_INTERVENTION): None of the LifeWrap compression garment straps will be secured.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women greater than or equal to (≥) 18 years of age~* Non-metastatic primary invasive adenocarcinoma of the breast clinical stage I to IIIC, including inflammatory and multicentric/multifocal breast cancer, with tumor size ≥1 centimeter (cm) by ultrasound or ≥2 cm by palpation, centrally confirmed HER2-positive (immunohistochemical score \[IHC\] 3+ or in situ hybridization \[ISH\]-positive)~* At least 1 measurable lesion in breast or lymph nodes (≥1 cm by ultrasound or ≥2 cm by palpation), except for inflammatory carcinoma (T4d)~* Baseline left ventricular ejection fraction (LVEF) ≥55%~* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1~* Adequate organ function at Baseline~Exclusion Criteria:~* History of any prior (ipsilateral and/or contralateral) invasive breast carcinoma~* Past or current history of malignant neoplasms, except for curatively treated basal and squamous cell carcinoma of the skin and in situ carcinoma of the cervix~* Metastatic disease~* Any prior therapy with anthracyclines~* Prior anti-HER2 therapy or biologic or immunotherapy~* Serious cardiac illness~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Herceptin IV + Chemotherapy (Type: ACTIVE_COMPARATOR): Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
- Herceptin SC + Chemotherapy (Type: EXPERIMENTAL): Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients who are 18 years or older~* Patients who are scheduled to undergo an open abdominal surgery (including laparoscopic-assisted) under general anesthesia or spinal anesthesia that does not include intrathecal opioids during the operation.~* Post-surgical patients who have been admitted to the PACU and are expected to remain hospitalized and to have acute post-operative pain requiring parenteral opioids for at least 48 hours after surgery.~Exclusion Criteria:~* Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).~* Patients with an allergy or hypersensitivity to opioids.~* Female patients who are pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sufentanil NanoTab PCA System/15 mcg (Type: EXPERIMENTAL): None
- Placebo Sufentanil NanoTab PCA System (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected~* Age ≥ 18 years~* Abtiretroviral-naïve, including above 7 days of cumulative prior antiretroviral therapy at any time prior to study entry.~* For women of childbearing potential: acceptance to use effective contraceptive methods~* Provision of written informed consent~Exclusion Criteria:~* Infection with HIV-1 group O, N, P~* Infection or co-infection with HIV-2~* Absolute neutrophil count (ANC) \< 500 cells/mm3~* Hemoglobin \< 7.0 g/dL~* Platelet count \< 50,000 cells/mm3~* AST and/or ALT \> 5 x Upper Limit of Normal (ULN)~* Calculated creatinine clearance \< 50 mL/min~* Active opportunistic or severe disease not under adequate control~* For women of childbearing age : Pregnancy/breastfeeding~* History or presence of allergy and/or contraindications to the trial drugs or their components~* Severe psychiatric illness~* Severe hepatic failure Patients co-infected with tuberculosis (TB), receiving a TB treatment and with stable clinical condition will not be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dolutegravir (Type: EXPERIMENTAL): Dolutegravir 50 mg Quaque die (QD) + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg Fixed Dose Combination (FDC) QD
- Efavirenz (Type: ACTIVE_COMPARATOR): Efavirenz 400 mg QD + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg FDC QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 1 year (or corrected age of 1 year, for those born prematurely) to 11 years for children (those who turn 12 over the study period will not be enrolled), and 18 and older~2. Diagnosed with a dry scalp condition with and IGA score of 2 of greater by a board-certified Dermatologist, Allergist, or Pediatrician~3. Good general health~4. Participant and/or their parent are able to read, write, and understand study materials in English~Exclusion Criteria:~1. Infants younger than 1 year old and between the ages of 12 and 18 (those who turn 12 over the study period will not be enrolled)~2. Patients diagnosed with other scalp diseases such as psoriasis, tinea capitis, and pediculosis capitis~3. Systemic steroid or oral antibiotic use during the past two months~4. Allergy to any of the preparation components

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Adults (Type: EXPERIMENTAL): All adults in the study will receive the treatment for dry scalp.
- Children (Type: EXPERIMENTAL): All children in the study will receive the treatment for dry scalp.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum 19 years old~* Kellgren stage I \~ III by ACR criteria~* Stable osteoarthritis during 3 months~* Be able to perform WOMAC and KKS~* Written consent form voluntarily~Exclusion Criteria:~* Disease of orthopaedic surgical that could affect to evaluate the efficacy~* Medication of continuous corticosteroid by oral or articular cavity within 12 weeks~* Medication of constantly (more than 1 week) antipsychotic drug or narcotic analgesics within four weeks~* Medical history of hypersensitivity reaction against Herbal drug~* Genetic factors as galactose intolerance, lapplactase deficiency or glucose-galactose malabsorption, etc.~* Occurrence of OA caused by the injury~* Diagnosed with psychical disorder, and taking medication~* Diagnosed with active peptic ulcers, gastrointestinal bleeding, inflammatory bowel disease, severe liver dysfunction, severe renal dysfunction, congestive heart failure, clinically significant ischemic heart disease, peripheral arterial disease, or cerebrovascular diseases~* Diagnosed with esophagus and gastrointestinal ulceration within 1 year, or treated it~* Abnormal bleeding (abnormal of platelet or blood coagulation factor, etc.)~* Positive in fecal occult blood test~* Gastrointestinal tract surgery except appendectomy~* Serum creatinine, ALT, AST, total bilirubin over UNL x 1.5 at screening test~* Participation in another clinical trials within 4 weeks~* Not consent about using effectual contraception method during trial~* Pregnant or lactating woman~* Medical history of malignant tumor within 5 years~* Investigator's judgment

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Shinbaro (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals with a confirmed COVID-19 viral infection, as determined by a qualified laboratory test. A nasal swab or saliva test analyzed by qPCR for COVID19.~2. Individuals who agree to abstain from sexual intercourse, or agree to use condoms or vaginal diaphragms or other devices designed to prevent contraception, during the entire course of the study~Exclusion Criteria~1. Viral infections other than COVID-19.~2. Clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina~3. Pregnancy~4. Females of child bearing potential age not on adequate contraception or lactating~5. Subjects receiving systemic corticosteroid treatment within one month of Screening Visit~6. Subjects Less than 18 years of age~7. Hospitalization within last 6 months due to acute exacerbation of airway disease~8. Subjects with a clinically significant abnormal chest x-ray within past 12 months~9. Medication changes within one month of study entry~10. Subjects who have participated in another investigation drug treatment study within the previous month.~11. Subjects with a current history of alcohol or recreational drug abuse.~12. Subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit.~Inclusion of Women and Minorities Every attempt will be made to include all genders, and minorities that present with an active COVID-19 infection that are not exempted due to exclusion criteria.~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Treatment of COVID-19 infected patients with a sodium pyruvate nasal spray (Type: EXPERIMENTAL): In this arm, patients will be provided with N115 sodium pyruvate nasal spray and instructed to use it 3x daily for 14 days. This group will be compared to the placebo control group to determine if sodium pyruvate reduces the symptoms, duration and replication of COVID-19 infection.
- Placebo control treatment of COVID-19 infected patients (Type: PLACEBO_COMPARATOR): In this arm, patients will be provided with a saline nasal spray as a placebo control. Patients will use the saline nasal spray 3x daily for 14 days, similar to the sodium pyruvate drug arm. This will serve as a control for the symptoms, duration and replication of COVID-19 infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Infant Shared Book Reading

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infants will be included if they are typically developing and between 5.5 and 12.5 months of age, as well as their caregiver.~* Parents 18-65 years old~Exclusion Criteria:~1. Infants who were born more that 14 days premature.~2. Infants who with a history of neurological or visual deficits.~3. Infants with a history of seizures or a disorder that includes risk of seizures.~4. Infants with a parent that has a history of seizures of a disorder that includes risk of seizures.~5. Parents with a history of seizures or a disorder that includes risk of seizures.

- Gender: ALL
- Minimum Age: 5 Months
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Effects of shared book reading (Type: EXPERIMENTAL): There will be one arm since all participants will undergo the same intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human Prolactin for Lactation Induction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women, aged 18-45 years~* Prolactin deficiency due to congenital deficiency, surgery or radiation, or Sheehan's syndrome during the current or previous pregnancies, for women who desire to breastfeed their infants.~* Postpartum at the time of study participation~* Milk must fail to come in by 2-4 days after delivery.~* Prolactin levels will be less than the lower limit of normal for the assay performed. If a subject is postpartum, prolactin levels will be less than the normal range for postpartum women (\<= 138.0 ± 11.9 ng/mL).~* Free T4 index must be normal either on or off thyroid hormone replacement.~* Fasting am cortisol or 1 hour Cortrosyn 0.25 mg stimulated cortisol must be normal (\>18 mg/dL). If it is not normal, subjects must be on glucocorticoid replacement and have no symptoms of adrenal insufficiency.~* History of normal spontaneous puberty or Tanner stage V breast development after previous estrogen replacement therapy.~Exclusion Criteria:~* Current use of medications known to increase or decrease prolactin~* Anatomical breast abnormalities~* Previous mammoplasty~* Breast augmentation~* Current use of hormonal contraception~* Allergies to mannitol~* Medications contraindicated for breastfeeding mothers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- recombinant human prolactin treatment (Type: EXPERIMENTAL): Open label twice daily recombinant human prolactin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Difluprednate in the Treatment of Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of endogenous anterior uveitis in at least 1 eye~Exclusion Criteria:~* Presence of intermediate uveitis, posterior uveitis or panuveitis~* Corneal abrasion~* Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease~* Allergy to similar drugs, such as other corticosteroids

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete